When Sam was diagnosed with a complex presentation of T-cell lymphoblastic lymphoma (T-LBL), his family and care team faced extraordinary challenges. As a young boy living with Down syndrome, his care required special medical support, family devotion and a strong community around them. Sam's story is featured as part of the Medical Stories docuseries, independently produced with Jazz Pharmaceuticals as a series sponsor.

Nick shares his experience recognizing early signs of stomach cancer, navigating diagnosis, learning the importance of HER2 testing, and finding strength through treatment, family support, and hope for the future. 

Armando’s journey with cholangiocarcinoma (CCA), a rare biliary tract cancer, reflects the power of connection and resilience. Throughout his experience, he shared how the support of loved ones brought him strength and peace. His words continue to inspire the cancer community, honoring the courage and spirit he carried into every conversation.

Discover how advancing HER2 science is reshaping cancer care. By deepening understanding of tumor complexity and leveraging biomarker-driven approaches, we are enabling more precise therapies and driving innovation to improve outcomes for patients with HER2-expressing cancers and other areas of high unmet need.

Extensive-stage small cell lung cancer remains one of the most aggressive and difficult-to-treat cancers, with most patients relapsing within months of initial therapy. Maintenance therapy may turn the period of stability after their first treatment into an opportunity to extend response and delay relapse.

We strive to put patient priorities first in our research, advancing our understanding of sleep conditions and the needs of those with narcolepsy and idiopathic hypersomnia.

We’ve placed a strategic focus on HER2 development to help address the ongoing unmet needs faced by patients and their families. Learn how the landscape of HER2-targeted agents in cancer care is evolving and how we’re continuing to build our HER2 platform to drive long-term impact for patients and their families

The pace of progress in oncology continues to accelerate, driven by a deeper understanding of tumor biology and increasingly precise therapeutic approaches. That momentum is particularly meaningful in rare cancers, where unmet need remains high and rigorous science has the potential to make a real difference for patients.

Corporate Sustainability and Social Impact, or CSSI, helps us embed the needs of patients, our people, communities, and the planet into how we operate and make decisions. It is a business discipline that supports trust, resilience, and long-term value.